Pharma BD Deal Intelligence
BI's animal health bet paid off into a durable #3 global franchise; Sanofi's reciprocal consumer-health leg ended up sold to private equity, not the clean strategic outcome either side originally pitched.
Full analysis, sources & comparables →Leerink's Seamus Fernandez: 'we certainly did not expect this move at this point in time.' Bernstein's Tim Anderson: 'strategically, Sanofi's scope of business…
FiercePharma framed it as both companies 'aiming for top dog status' in their respective focus areas, citing Morningstar's Damien Conover that scale and…
C&EN: the cash-and-asset swap is a textbook example of two companies trading non-core franchises to achieve global category leadership in their respective…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boehringer Ingelheim and Sanofi entered a binding business swap: Boehringer acquired Sanofi's Merial animal health business (~euro 11.4B / $12.4B) in exchange for Boehringer's Consumer Healthcare business (~euro 6.7B) plus a euro 4.7B cash payment. Created the world's #2 animal health company. Closed January 1, 2017.
BI's animal health bet paid off into a durable #3 global franchise; Sanofi's reciprocal consumer-health leg ended up sold to private equity, not the clean strategic outcome either side originally pitched.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) (this deal) | 2015 | $12.4B | 81 |
| Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. | 2021 | — | — |
| Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG | 2023 | $508M | — |
| Boehringer Ingelheim International GmbH / Cue Biopharma, Inc. | 2025 | $357M | — |
| Boehringer Ingelheim International GmbH / Synaffix B.V. | 2025 | $1.3B | — |
| Boehringer Ingelheim International GmbH / Immunitas Therapeutics, Inc. | 2026 | — | — |
| Boehringer Ingelheim International GmbH / Immunai Inc. | 2026 | $15M | — |
← Browse all deals · How we score deals
More: 2015 deals · Boehringer Ingelheim International GmbH deals · Vaccines deals